Table 1. Association between miR-210 expression and different clinicopathological features of gliomas.
| Clinicopathological parameters | No. of cases | miR-210 expression | P-value |
|---|---|---|---|
| Sex; male | 70 | 9.34±7.02 | 0.42 |
| Sex; female | 56 | 8.40±6.02 | |
| Age; <44 years | 74 | 9.20±6.64 | 0.44 |
| Age; ⩾44 years | 52 | 8.29±6.26 | |
| WHO grade; I; PA | 13 | 2.87±1.41 | <0.001 |
| WHO grade; II; DA | 35 | 4.99±2.79 | |
| WHO grade; III; AA | 46 | 10.88±6.16 | |
| WHO grade; IV; GBM | 32 | 12.48±7.29 | |
| Tumour size; ⩾5 cm | 59 | 8.30±5.97 | 0.40 |
| Tumour size; <5 cm | 67 | 9.28±6.90 | |
| KPS; <90 | 53 | 9.65±6.62 | 0.09 |
| KPS; ⩾90 | 73 | 7.69±6.15 |
Abbreviations: AA=anaplastic astrocytomas; DA=diffuse astrocytomas; GBM=glioblastoma multiforme; KPS=Karnofsky Performance Scale; PA=pilocytic astrocytomas; WHO=World Health Organisation. The median age was 44 years.